• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Marker Therapeutics Inc.

    5/15/25 4:13:40 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Marker Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    57055L206

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    57055L206


    1Names of Reporting Persons

    Blue Owl Capital Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,127,052.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,127,052.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,127,052.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  The reported securities represent 554,250 shares of common stock ("Common Stock") and 572,802 shares of Common Stock issuable upon exercise of Warrants (as defined below) to purchase shares of Common Stock from the Issuer. The percentage of class is calculated based upon 10,709,005 shares of Common Stock outstanding as of March 18, 2025, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 31, 2025, as increased by the 572,802 shares of Common Stock issuable upon exercise of the Warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Marker Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas, 77021
    Item 2. 
    (a)Name of person filing:

    Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
    (b)Address or principal business office or, if none, residence:

    399 Park Avenue New York, NY 10022
    (c)Citizenship:

    See response to Item 4 on the cover page.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    57055L206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on the cover page. At a special meeting on March 21, 2025, stockholders approved the issuance of shares of Common Stock upon exercise of warrants held by the Reporting Person, each exercisable to receive one share of Common Stock (the "Warrants"). In this regard, the Reporting Person holds 554,250 shares of Common Stock and 2,570,750 Warrants, which are subject to a conversion limitation that prevents the Reporting Person's beneficial ownership from exceeding 9.99%. As such, the reported securities include only 572,802 shares of Common Stock acquirable upon exercise of Warrants. The filing of this Statement shall not be construed as an admission that the Reporting Person or any of the foregoing are, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement.
    (b)Percent of class:

    See response to Item 11 on the cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on the cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on the cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on the cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Blue Owl Capital Holdings LP
     
    Signature:/s/ Karen Hager
    Name/Title:Karen Hager / Chief Compliance Officer
    Date:05/15/2025
    Get the next $MRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Elms Steve

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:20:34 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Knobil Katharine

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:19:38 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Eansor Norman David

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:18:35 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/26/24 4:01:17 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/23/24 4:40:48 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

      HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc

      4/1/25 8:00:14 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

      Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 Strategic financing to support cli

      3/31/25 8:45:00 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Financials

    Live finance-specific insights

    See more
    • Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

      Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

      2/16/22 4:30:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

      HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

      2/8/22 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

      HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

      11/10/21 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

      CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

      8/28/24 8:00:00 AM ET
      $KRRO
      $MRKR
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St

      3/25/24 5:45:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/17/24 6:25:14 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/26/21 10:38:04 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/15/21 4:45:13 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    SEC Filings

    See more
    • Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/20/25 8:32:01 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Marker Therapeutics Inc.

      10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/15/25 5:00:50 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marker Therapeutics Inc.

      SCHEDULE 13G/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/15/25 4:13:40 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Marker International with a new price target

      Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

      3/5/25 7:37:58 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics downgraded by Roth Capital with a new price target

      Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      2/17/22 6:14:24 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Marker Therapeutics with a new price target

      Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

      3/25/21 6:18:22 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care